
Mentor: Chandra Sehgal, PhD
Hiring Department: Radiology
Funding Source: NIH
Number of positions: 1
U.S. Citizens and foreign nationals may apply
Project overview
The ultrasound research lab is developing hydralazine-augmented contrast ultrasound (HyCUS), a novel functional imaging technique that exploits differences in tumor versus liver vasculature to improve early detection of hepatocellular carcinoma (HCC), the fastest-growing cause of cancer death in the U.S. Our preliminary data show HyCUS more than triples lesion visibility compared to standard B-mode and contrast-enhanced ultrasound, and detects small HCC lesions missed entirely by current clinical methods. We are seeking a motivated postdoctoral fellow to help translate this promising discovery from bench to bedside.
Research Activity
The candidatewill lead validation studies in an autochthonous rat model of HCC with liver fibrosis, working across three interconnected aims: establishing the biological basis of HyCUS, defining an optimal hydralazine dosing regimen, and benchmarking HyCUS against existing sonographic surveillance methods. The investigator will work at the intersection of cancer biology, vascular pharmacology, and noninvasive imaging. The position provides an opportunity to shape a translational imaging technology from preclinical proof of concept toward eventual clinical application.
We will provide training in any missing technical skills for motivated candidates.
To apply, please submit the following through Interfolio:
The University of Pennsylvania is an equal opportunity employer. Candidates are considered for employment without regard to race, color, sex, sexual orientation, religion, creed, national origin (including shared ancestry or ethnic characteristics), citizenship status, age, disability, veteran status or any class protected under applicable federal, state, or local law.
